Dexcom (DXCM)

DexCom, Inc. empowers people to take control of diabetes through innovative continuous glucose monitoring (CGM) products. Headquartered in San Diego, California, Dexcom has emerged as a leader of diabetes care technology. By listening to the needs of patients, caregivers, and clinicians, Dexcom simplifies and improves diabetes management around the world.

Company profile

Kevin Sayer
Fiscal year end
SweetSpot Diabetes Care, Inc. • TypeZero Technologies, Inc. • DexCapital, LLC • The Glucose Program, LLC • Nintamed Handels GmbH • DexCom Canada, Co. • DexCom (Canada) Inc. • DexCom Deutschland GmbH • DexCom (Malayisa) Sdn Bhd. • DexCom Philippines, Inc. ...
IRS number

DXCM stock data

Investment data

Data from SEC filings
Securities sold
Number of investors


28 Apr 22
17 May 22
31 Dec 22
Quarter (USD) Mar 22 Dec 21 Sep 21 Jun 21
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS
Annual (USD) Dec 21 Dec 20 Dec 19 Dec 18
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS
Cash burn rate (est.) Burn method: Change in cash Burn method: Operating income Burn method: FCF (opex + capex)
Last Q Avg 4Q Last Q Avg 4Q Last Q Avg 4Q
Cash on hand (at last report) 717.1M 717.1M 717.1M 717.1M 717.1M 717.1M
Cash burn (monthly) 112.17M 1.42M (no burn) (no burn) (no burn) (no burn)
Cash used (since last report) 174.07M 2.21M n/a n/a n/a n/a
Cash remaining 543.03M 714.89M n/a n/a n/a n/a
Runway (months of cash) 4.8 501.7 n/a n/a n/a n/a

Beta Read what these cash burn values mean

Date Owner Security Transaction Code Indirect 10b5-1 $Price #Shares $Value #Remaining
9 May 22 Chad Patterson Common Stock Sell Dispose S No Yes 342.77 777 266.33K 13,675
25 Apr 22 Pacelli Steven Robert Common Stock Sell Dispose S No Yes 439.94 250 109.99K 35,425
11 Apr 22 Chad Patterson Common Stock Sell Dispose S No Yes 498.75 776 387.03K 14,452
29 Mar 22 Barry J. Regan Common Stock Sell Dispose S No Yes 500 1,106 553K 16,345
23 Mar 22 Pacelli Steven Robert Common Stock Sell Dispose S No Yes 459.98 250 115K 35,675
93.2% owned by funds/institutions
13F holders Current Prev Q Change
Total holders 910 778 +17.0%
Opened positions 190 117 +62.4%
Closed positions 58 48 +20.8%
Increased positions 334 272 +22.8%
Reduced positions 265 264 +0.4%
13F shares Current Prev Q Change
Total value 49.1B 50.28B -2.4%
Total shares 91.45M 92.01M -0.6%
Total puts 1.91M 1.59M +20.4%
Total calls 1.64M 1.92M -14.7%
Total put/call ratio 1.2 0.8 +41.1%
Largest owners Shares Value Change
Vanguard 10.41M $5.59B +0.6%
BLK Blackrock 8.13M $4.36B +6.6%
FMR 4.54M $2.44B -0.2%
Baillie Gifford & Co 4.51M $2.42B -15.7%
STT State Street 4.05M $2.17B +3.4%
Sands Capital Management 3.13M $1.68B -5.9%
JPM JPMorgan Chase & Co. 2.93M $1.57B -2.0%
Capital Research Global Investors 2.37M $1.28B +55.2%
Nuveen Asset Management 2.05M $1.1B -2.2%
Geode Capital Management 1.87M $1B +4.1%
Largest transactions Shares Bought/sold Change
Lone Pine Capital 0 -1.44M EXIT
Capital Research Global Investors 2.37M +844.92K +55.2%
Baillie Gifford & Co 4.51M -840.63K -15.7%
JHG Janus Henderson 1.82M -798.82K -30.5%
Norges Bank 764.82K +764.82K NEW
Artisan Partners Limited Partnership 1.05M -725.47K -40.9%
WFC Wells Fargo & Co. 420.04K -578.01K -57.9%
BLK Blackrock 8.13M +500.22K +6.6%
Allspring Global Investments 490.07K +490.07K NEW
Wellington Management 511.59K -472.22K -48.0%

Financial report summary

  • If we experience decreasing prices for our products and we are unable to reduce our expenses, including the per unit cost of producing our products, there may be a material adverse effect on our business, results of operations, financial condition and cash flows.
  • We are subject to cost-containment efforts by third-party payors that could result in reduced product pricing and/or sales of our products and cause a reduction in future revenue.
  • Although many third-party payors have adopted some form of coverage policy on continuous glucose monitoring devices, our products do not always have some form of coverage, including simple broad-based contractual coverage, with third-party payors and we frequently experience administrative challenges in obtaining reimbursement for our customers. If we are unable to obtain adequately broad reimbursement at acceptable prices for our products or any future products from third-party payors, our revenue may be negatively impacted.
  • The research and development efforts we undertake independently, and in some instances in connection with our collaborations with third parties, may not result in the development of commercially viable products, the generation of significant future revenues or adequate profitability.
  • Our products may not achieve or maintain market acceptance.
  • If our manufacturing capabilities are insufficient to produce an adequate supply of product at appropriate quality levels, our growth could be limited and our business could be harmed.
  • Manufacturing difficulties and/or any disruption at our facilities may adversely affect our manufacturing operations and related product sales, and increase our expenses.
  • We depend upon third-party suppliers and outsource to other parties, making us vulnerable to supply disruptions, suboptimal quality, non-compliance and/or price fluctuations, which could harm our business.
  • If we are unable to establish and maintain adequate sales, marketing and distribution capabilities or enter into and maintain arrangements with third parties to sell, market and distribute our products, we may have difficulty achieving market awareness and selling our products in the future.
  • We operate in a highly competitive market and face competition from large, well-established companies with significant resources, and, as a result, we may not be able to compete effectively.
  • The outbreak of the SARS-CoV-2 virus and its variants and the COVID-19 disease that it causes, or similar public health crises, could have a material adverse impact on our business, financial condition and results of operations, including our manufacturing, commercial operations and sales.
  • We are subject to a variety of risks due to our international operations that could adversely affect our business, our operations or profitability and operating results.
  • Laws and regulations governing the export of our products could adversely impact our business.
  • The failure to comply with U.S. Foreign Corrupt Practices Act and similar worldwide anti-bribery laws in non-U.S. jurisdictions could materially adversely affect our business and result in civil and/or criminal sanctions.
  • Current uncertainty in global economic and political conditions makes it particularly difficult to predict product demand and other related matters and makes it more likely that our actual results could differ materially from expectations.
  • Failure to obtain any required regulatory authorization in foreign jurisdictions will prevent us from marketing our products abroad.
  • We are subject to complex and evolving U.S. and foreign laws and regulations and other requirements regarding privacy, data protection, security, and other matters. Many of these laws and regulations are subject to change and uncertain interpretation, and could result in claims, changes to our business practices, monetary penalties, increased cost of operations, or declines in user growth or engagement, or otherwise harm our business.
  • Security breaches and other disruptions that compromise our information and expose us to liability could cause our business and reputation to suffer and could subject us to substantial liabilities.
  • Cybersecurity risks and cyber incidents could result in the compromise of confidential data or critical data systems and give rise to potential harm to customers, remediation and other expenses, expose us to liability under HIPAA, consumer protection laws, or other common law theories, subject us to litigation and federal and state governmental inquiries, damage our reputation, and otherwise be disruptive to our business and operations.
  • Failure to protect our information technology infrastructure against cyber-based attacks, network security breaches, service interruptions, or data corruption could significantly disrupt our operations and adversely affect our business and operating results.
  • Cyber attacks aimed at accessing our devices, products, and services, or related devices, products, and services, and modifying or using them in a way inconsistent with our FDA clearances and approvals could create risks to users.
  • We conduct business in a heavily regulated industry and if we fail to comply with applicable laws and government regulations, we could become subject to penalties, be excluded from participation in government programs, and/or be required to make significant changes to our operations.
  • If we or our suppliers or distributors fail to comply with ongoing regulatory requirements, or if we have unanticipated problems with our products, the products could be subject to restrictions or withdrawal from the market.
  • Quality problems could lead to recalls or safety alerts, reputational harm, and could have a material adverse effect on our business, results of operations, financial condition and cash flows.
  • Potential long-term complications from our current or future products or other CGM systems under development may not be revealed by our clinical experience to date.
  • We may never receive approval, marketing authorization or clearance from the U.S. FDA and other governmental agencies to market additional CGM systems, expanded indications for use of current and future generation CGM systems, future software platforms, or any other products under development.
  • Our failure to comply with laws, regulations and contract requirements relating to reimbursement of health care goods and services may subject us to penalties and adversely impact our reputation, business, financial condition and cash flows.
  • Managed care trends and consolidation in the health care industry could have an adverse effect on our revenues and results of operations.
  • If we are unable to successfully complete the pre-clinical studies or clinical trials necessary to support additional PMA, de novo, or 510(k) applications or supplements, we may be unable to commercialize our CGM systems under development, which could impair our business, financial condition and operating results.
  • Changes to the regulatory landscape may impact our ability to obtain marketing authorization for future product developments.
  • The commencement or completion of any of our clinical trials may be delayed or halted, or be inadequate to support approval of FDA marketing applications or supplements, for numerous reasons, including, but not limited to, the following:
  • Our CGM systems currently have regulatory marketing authorization limited to individual patient home-use, and have otherwise not received clearance or approval from the FDA or other regulators for use in hospital or other in-patient facility settings, although the FDA has advised us that it will not object to the use of our CGM systems in such settings during the COVID-19 pandemic. Our potential supply of our CGM systems for use in this environment during the COVID-19 pandemic may present risks to our business.
  • We depend on clinical investigators and clinical sites to enroll patients in our clinical trials and other third parties to manage the trials and to perform related data collection and analysis, and, as a result, we may face costs and delays that are outside of our control.
  • Health care policy changes, including U.S. health care reform legislation, may have a material adverse effect on our business.
  • We are subject to claims of infringement or misappropriation of the intellectual property rights of others, which could prohibit us from shipping affected products, require us to obtain licenses from third parties or to develop non-infringing alternatives, and subject us to substantial monetary damages and injunctive relief. We may also be subject to other claims or suits.
  • Our inability to adequately protect our intellectual property could allow our competitors and others to produce products based on our technology, which could substantially impair our ability to compete.
  • We face the risk of product liability claims and may be subject to damages, fines, penalties and injunctions, among other things.
  • We could become the subject of governmental investigations, claims and litigation.
  • We may be subject to fines, penalties and injunctions if we are determined to be promoting the use of our products for unapproved or improper off-label uses or determined to have made claims that are untruthful or misleading or not adequately substantiated.
  • In some instances in our advertising and promotion, we may make claims regarding our product as compared to competing products, which may subject us to heightened regulatory scrutiny, enforcement risk, and litigation risks.
  • Direct-to-consumer marketing and social media efforts may expose us to additional regulatory scrutiny.
  • We have incurred significant losses in the past and may incur losses in the future.
  • Our success will depend on our ability to attract and retain our personnel and manage our human capital, while controlling labor costs.
  • We may conduct additional financings to continue the development or commercialization of our current or future generation CGM systems.
  • Uncollectible uninsured and patient due accounts could adversely affect our results of operations.
  • Changes in our business strategy or restructuring of our businesses may increase our costs or otherwise affect the profitability of our businesses or the value of our assets.
  • We may face risks associated with acquisitions of companies, products and technologies and our business could be harmed if we are unable to address these risks.
  • Compliance with regulations relating to public company corporate governance matters and reporting may strain our resources and divert management’s attention.
  • We could be subject to changes in our tax rates, new U.S. or international tax legislation or additional tax liabilities.
  • Our ability to use our net operating losses to offset future taxable income may be subject to certain limitations which could subject our business to higher tax liability.
  • Valuation of share-based payments, which we are required to perform for purposes of recording compensation expense under authoritative guidance for share-based payment, involves assumptions that are subject to change and difficult to predict.
  • Our stock price is highly volatile and investing in our stock involves a high degree of risk, which could result in substantial losses for investors.
  • The issuance of shares by us in the future or sales of shares by our stockholders may cause the market price of our common stock to drop significantly, even if our business is performing well.
  • We do not intend to pay dividends for the foreseeable future.
  • Anti-takeover effects of our charter documents and Delaware law could make a merger, tender offer or proxy contest difficult, thereby depressing the trading price of our common stock.
  • Increasing our financial leverage could affect our operations and profitability.
  • Failure to comply with covenants in the Amended Credit Agreement could result in our inability to borrow additional funds and adversely impact our business.
  • We have indebtedness in the form of convertible senior notes, which could adversely affect our financial health and our ability to respond to changes in our business.
  • We may be unable to repurchase the Notes upon a fundamental change when required by the holders or repay prior to maturity any accelerated amounts due under the notes upon an event of default or redeem the Notes unless specified conditions are met under our Credit Facility, and our future debt may contain additional limitations on our ability to pay cash upon conversion, repurchase or repayment of the Notes.
  • We may still incur substantially more debt or take other actions which would intensify the risks discussed above.
  • The convertible note hedge and warrant transactions may affect the value of the 2023 Notes and our common stock.
  • We are subject to counterparty risk with respect to the 2023 Note Hedge transactions.
  • Servicing our debt requires a significant amount of cash, and we may not have sufficient cash flow from our business to pay our substantial debt.
  • Our Credit Facility imposes restrictions on us that may adversely affect our ability to operate our business.
  • Conversion of the Notes will, to the extent we deliver shares upon conversion of such Notes, dilute the ownership interest of existing stockholders, including holders who had previously converted their Notes, or may otherwise depress our stock price.
  • The conditional conversion feature of the Notes, if triggered, may adversely affect our financial condition and operating results.
  • The accounting method for convertible debt securities that may be settled in cash, such as the Notes, may have a material effect on our reported financial results.
  • The fundamental change repurchase feature of the Notes may delay or prevent an otherwise beneficial attempt to take over Dexcom.
  • Current uncertainty in domestic and global economic and political conditions makes it particularly difficult to predict product demand and other related matters and makes it more likely that our actual results could differ materially from expectations.
  • If we are unable to successfully maintain effective internal control over financial reporting, investors may lose confidence in our reported financial information and our stock price and our business may be adversely impacted.
  • Changes in financial accounting standards or practices or existing taxation rules or practices may cause adverse unexpected revenue and/or expense fluctuations and affect our reported results of operations.
  • If our financial performance fails to meet the expectations of investors and public market analysts, the market price of our common stock could decline.
  • We may be liable for contamination or other harm caused by materials that we handle, and changes in environmental regulations could cause us to incur additional expense.
  • Environmental, social and corporate governance, or ESG, regulations, policies and provisions may make our supply chain more complex and may adversely affect our relationships with customers.
  • Our business could be negatively impacted by corporate citizenship and ESG matters and/or our reporting of such matters.
  • Climate change may have a long-term impact on our business.

Content analysis

H.S. junior Avg
New words: ABR, add, adjunctive, AdvaMed, ahead, alcohol, Alphabet, annum, attendance, attendee, AUD, bifurcation, BKBM, Blueprint, categorized, CDOR, certainty, chronic, clarified, clarify, Codification, companion, contact, contrast, corollary, counsel, deposit, deprioritization, diagnosed, dispensing, earliest, empower, engineering, entertainment, EURIBOR, factory, feasible, fringe, Governor, gradual, half, headcount, history, horizon, inflationary, injection, Interbank, Ireland, jointly, Journal, land, layer, leaving, legacy, LIBO, London, main, Malaysian, meal, milestone, month, multiplied, nonconvertible, NYFRB, older, onsite, overhead, overturned, Penang, penetrate, pharmaceutical, phase, phased, PhRMA, pipeline, programmatic, quick, recoverable, regular, reopening, Reserve, reversed, RFR, Ringgit, Safer, salary, scrap, sooner, sponsor, STIBOR, Stockholm, supervision, TIBOR, Tokyo, tracing, trajectory, troubled, Ukraine, uncured, understood, upfront, usage, vast, vintage, war, warehouse
Removed: accruing, age, authorize, build, deficit, earlier, EBITDA, examine, HealthCanada, hereof, indirect, line, maintained, Onduo, overnight, persisting, PPE, precluded, Presidential, proper, Reclassification, relator, repeal, repealed, repurchased, restructured, revised, simplify, Simplifying, structured, subsequently, terrorist, timed, tracking, unrestricted, zone